What Lake Forest Regenesis’s Emsculpt NEO launch reveals about the future of device-led metabolic care
Lake Forest Regenesis launches Emsculpt NEO and Emsella. Discover what this means for noninvasive devices, regulation, and clinical adoption.
Why GE HealthCare’s FDA-cleared SIGNA MRI update is more about operations than image quality
GE HealthCare’s FDA-cleared SIGNA MRI systems signal a shift toward autonomous, helium-free imaging. Explore what this means for MRI operations.
What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Why Sibel Health’s Aria sensor could change endpoint design in chronic refractory cough trials
Sibel Health secures FDA acceptance for its Aria cough sensor. Find out what this could change for chronic cough drug trials and digital endpoints.
Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.
Bimini Health Tech strengthens Puregraft franchise with SYNC as fat grafting scales globally
Bimini Health Tech secures FDA clearance for Puregraft SYNC. Explore what it changes for fat grafting workflows, adoption economics, and device strategy.
From ingredients to devices: what BON Natural Life Limited’s apple mask means for medical aesthetics innovation
Explore how BON Natural Life Limited’s bio-electronic apple polyphenol mask could reshape medical aesthetics if clinical data holds up.
Life Spine strengthens ProLift’s long-term viability as MRI compatibility becomes a procurement baseline
Life Spine confirms MR Conditional status for ProLift. Find out why MRI compatibility now defines spine implant viability rather than differentiation.
Why Project Santa Fe Foundation and Virchow Medical are testing a proactive future for oncology diagnostics
Project Santa Fe Foundation and Virchow Medical are redefining oncology diagnostics through proactive analytics. Find out what this changes for labs and clinicians.
Next-generation SIGNA MRI gains FDA nod, sharpening GE HealthCare’s imaging strategy
GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.